[{"orgOrder":0,"company":"Shift Bioscience","sponsor":"BGF","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"Gene-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Shift Bioscience","amount2":0.02,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Shift Bioscience \/ BGF","highestDevelopmentStatusID":"14","companyTruncated":"Shift Bioscience \/ BGF"}]

Find Clinical Drug Pipeline Developments & Deals by Shift Bioscience

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The proceeds will be used for Shift Bioscience’s AI cell simulation platform, for the identification of genes that can safely rejuvenate cells to combat the effects of age-related illnesses.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          October 15, 2024

                          Lead Product(s) : Gene-based Therapy

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Preclinical

                          Sponsor : BGF

                          Deal Size : $16.0 million

                          Deal Type : Financing

                          blank